Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Lineage Cell Therapeutics Analyst Ratings and Price Targets | AMEX:LCTX | Benzinga
Lineage Cell Therapeutics Inc has a consensus price target of $4.88 based on the ratings of 8 analysts. The high is $9 issued by HC Wainwright & Co. on March 11, 2025. The low is $2 issued by D. Boral Capital on March 11, 2025. The 3 most-recent analyst ratings were released by B. Riley Securities, D. Boral Capital, and HC Wainwright & Co. on March 14, 2025, March 11, 2025, and March 11, 2025, respectively. With an average price target of $4.67 between B. Riley Securities, D. Boral Capital, and HC Wainwright & Co., there's an implied 442.64% upside for Lineage Cell Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B. Riley Securities
D. Boral Capital
HC Wainwright & Co.
Maxim Group
Craig-Hallum
1calculated from analyst ratings
Analyst Ratings for Lineage Cell Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/14/2025 | Buy Now | 248.84% | B. Riley Securities | Mayank Mamtani72% | $4 → $3 | Maintains | Buy | Get Alert |
| 03/11/2025 | Buy Now | 132.56% | D. Boral Capital | Jason Kolbert51% | $2 → $2 | Maintains | Buy | Get Alert |
| 03/11/2025 | Buy Now | 946.51% | HC Wainwright & Co. | Joseph Pantginis46% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 946.51% | HC Wainwright & Co. | Joseph Pantginis46% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 132.56% | D. Boral Capital | Jason Kolbert51% | $3 → $2 | Maintains | Buy | Get Alert |
| 01/31/2025 | Buy Now | 946.51% | HC Wainwright & Co. | Joseph Pantginis46% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 01/10/2025 | Buy Now | 248.84% | Maxim Group | Michael Okunewitch34% | $5 → $3 | Maintains | Buy | Get Alert |
| 01/03/2025 | Buy Now | 132.56% | D. Boral Capital | Jason Kolbert51% | $2 → $2 | Maintains | Buy | Get Alert |
| 12/04/2024 | Buy Now | 946.51% | HC Wainwright & Co. | Joseph Pantginis46% | $7 → $9 | Maintains | Buy | Get Alert |
| 11/20/2024 | Buy Now | 132.56% | D. Boral Capital | Jason Kolbert51% | $3 → $2 | Maintains | Buy | Get Alert |
| 11/18/2024 | Buy Now | 248.84% | D. Boral Capital | Jason Kolbert51% | → $3 | Initiates | → Buy | Get Alert |
| 08/20/2024 | Buy Now | 365.12% | Craig-Hallum | Albert Lowe34% | → $4 | Initiates | → Buy | Get Alert |
| 05/06/2024 | Buy Now | 713.95% | HC Wainwright & Co. | Joseph Pantginis46% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | Buy Now | 713.95% | HC Wainwright & Co. | Joseph Pantginis46% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2024 | Buy Now | 713.95% | HC Wainwright & Co. | Joseph Pantginis46% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 02/05/2024 | Buy Now | 597.67% | Cantor Fitzgerald | Kristen Kluska71% | $6 → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 08/11/2023 | Buy Now | 713.95% | HC Wainwright & Co. | Joseph Pantginis46% | → $7 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2023 | Buy Now | 597.67% | Cantor Fitzgerald | Kristen Kluska71% | → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 07/24/2023 | Buy Now | 713.95% | HC Wainwright & Co. | Joseph Pantginis46% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | 713.95% | HC Wainwright & Co. | Joseph Pantginis46% | → $7 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2023 | Buy Now | 713.95% | HC Wainwright & Co. | Joseph Pantginis46% | → $7 | Reiterates | → Buy | Get Alert |
| 03/10/2023 | Buy Now | 713.95% | HC Wainwright & Co. | — | → $7 | Reiterates | → Buy | Get Alert |
| 11/02/2022 | Buy Now | 481.4% | Baird | Jack Allen 38% | → $5 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Lineage Cell Therapeutics (LCTX) stock?
The latest price target for Lineage Cell Therapeutics (AMEX:LCTX) was reported by B. Riley Securities on March 14, 2025. The analyst firm set a price target for $3.00 expecting LCTX to rise to within 12 months (a possible 248.84% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lineage Cell Therapeutics (LCTX)?
The latest analyst rating for Lineage Cell Therapeutics (AMEX:LCTX) was provided by B. Riley Securities, and Lineage Cell Therapeutics maintained their buy rating.
When was the last upgrade for Lineage Cell Therapeutics (LCTX)?
There is no last upgrade for Lineage Cell Therapeutics
When was the last downgrade for Lineage Cell Therapeutics (LCTX)?
There is no last downgrade for Lineage Cell Therapeutics.
When is the next analyst rating going to be posted or updated for Lineage Cell Therapeutics (LCTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lineage Cell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lineage Cell Therapeutics was filed on March 14, 2025 so you should expect the next rating to be made available sometime around March 14, 2026.
Is the Analyst Rating Lineage Cell Therapeutics (LCTX) correct?
While ratings are subjective and will change, the latest Lineage Cell Therapeutics (LCTX) rating was a maintained with a price target of $4.00 to $3.00. The current price Lineage Cell Therapeutics (LCTX) is trading at is $0.86, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
